CDT Equity Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.077 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 86.59K
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Details
| Name | CDT Equity Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 4 |
| Founded | 2019 |
| Ceo | James Bligh |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US20678X7003 |
| Cusip | 20678X700 |
| Cik | 1896212 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| James Bligh | Co-Founder, Chief Executive Officer and Director |
| Dr. Joanne M. Holland | Chief Scientific Officer |
| Dr. David Joszef Tapolczay | Head of Strategy and Licensing |
Contact
| Address | 4581 Tamiami Trail North, Suite 200, Naples, Florida 34103, United States |
| Phone | 646 491 9132 |
| Website | https://www.cdtequity.com |